Compare NATL & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | TLX |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2023 | 2024 |
| Metric | NATL | TLX |
|---|---|---|
| Price | $47.16 | $9.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $50.20 | $20.74 |
| AVG Volume (30 Days) | ★ 750.1K | 384.7K |
| Earning Date | 11-04-2026 | 10-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.98 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $4,354,000,000.00 | N/A |
| Revenue This Year | $2.59 | $16.05 |
| Revenue Next Year | $4.15 | $13.75 |
| P/E Ratio | ★ $40.70 | $150.33 |
| Revenue Growth | ★ 0.86 | N/A |
| 52 Week Low | $33.31 | $6.28 |
| 52 Week High | $48.50 | $13.11 |
| Indicator | NATL | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.65 | 34.20 |
| Support Level | $45.40 | $8.69 |
| Resistance Level | $48.23 | $9.70 |
| Average True Range (ATR) | 0.48 | 0.19 |
| MACD | 0.17 | -0.11 |
| Stochastic Oscillator | 97.46 | 2.62 |
NCR Atleos Corp is a financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers, and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels, all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware, and its proprietary Allpoint network. Atleos manages its operations in the following segments: Self-Service Banking, which generates maximum revenue, Network, and Telecommunications and Technology. Geographically, it derives maximum revenue from the U.S.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.